What is Absci?
Absci is a biotechnology company headquartered in Vancouver, Washington, dedicated to advancing the field of biologics. The company's core mission involves the creation of protein-based drugs and the engineering of E. coli to efficiently produce proteins and antibodies. This focus positions Absci at the forefront of developing novel therapeutic solutions, leveraging advanced biological engineering to address unmet medical needs. The company's work is critical for the next generation of drug discovery and development.
How much funding has Absci raised?
Absci has raised a total of $286.9M across 7 funding rounds:
Series A
$5.1M
Series C
$12M
Multiple Rounds
$80.8M
Other Financing Round
$125M
Other Financing Round
$64M
Series A (2016): $5.1M with participation from Oregon Venture Fund and Phoenix Venture Partners
Series C (2018): $12M led by Oregon Venture Fund, Phoenix Venture Partners, and Greenbridge Partners
Series D (2020): $15.4M supported by Columbia Ventures Corporation, Washington Research Foundation, JSR Life Sciences, Oregon Venture Fund, Phoenix Venture Partners, and KBI Biopharma
Debt (2020): $350K featuring PPP
Series E (2020): $65M backed by Casdin Capital
Other Financing Round (2021): $125M with participation from Redmile Group , LLC and Casdin Capital , LLC
Other Financing Round (2025): $64M, investors not publicly disclosed
Key Investors in Absci
Casdin Capital
Casdin Capital is a venture capital firm that brings deep understanding and expertise to financing life science innovation, with a specific focus on diagnostics and molecular information.
Washington Research Foundation
The Washington Research Foundation is an organization that supports scientific research and innovation, likely focusing on early-stage companies in the life sciences sector.
Phoenix Venture Partners
Phoenix Venture Partners is a venture capital firm specializing in transforming innovative technologies into market-ready products, with a focus on advanced materials, novel devices, and innovative manufacturing processes.
What's next for Absci?
With the recent strategic investment and substantial overall capital raised, Absci is poised for significant expansion and innovation. The company's trajectory suggests a focus on scaling its proprietary protein engineering platform and advancing its pipeline of protein-based therapeutics. Future developments are likely to involve further research and development, potential strategic partnerships within the pharmaceutical and biotech industries, and the continued pursuit of groundbreaking solutions in drug discovery. The enterprise-level backing indicates confidence in Absci's long-term vision and its capacity to deliver impactful biological innovations.
See full Absci company page
